Healthcare Analyst Yang discusses the recent data of Biomea Fusion’s Menin Inhibitor (BMF-219) in Type 2 Diabetes and what to expect at the upcoming American Diabetes Association’s 83rd Scientific Sessions on an Analyst/Industry conference call to be held on June 21 at 1 pm. (Webcast Link):(https://centurylink.cwebcast.com/ses/MYB0YTAvXj3wYYmRj6rZKQ~~)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- TipRanks ‘Perfect 10’ List: 3 Top-Rated Stocks That Tick All the Right Boxes
- Biomea Fusion Surges on New Buy Rating
- Biomea Fusion reports Q1 EPS (98c), consensus (81c)